Ignite Creation Date:
2024-05-05 @ 5:05 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00384475
Status:
COMPLETED
Last Update Posted:
2016-11-30
First Post:
2006-10-05
Brief Title:
A Study of Ciclesonide Nasal Spray in Patients 18 Years and Older With Seasonal Allergic Rhinitis BY9010M1-413
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A Randomized Double-blind Placebo-controlled Parallel-group Study Using the Environmental Exposure Chamber EEC to Assess the Onset of Action of Ciclesonide Applied as a Nasal Spray 200 mcg Once Daily in the Treatment of Seasonal Allergic Rhinitis SAR in Patients 18 Years and Older
Status:
COMPLETED
Status Verified Date:
2016-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to investigate the safety and effectiveness of ciclesonide nasal spray as compared with placebo inactive substance nasal spray in relieving symptoms of seasonal allergic rhinitis caused by pollen Ciclesonide will be administered once during the exposure to ragweed pollen in a controlled environment The study duration consists of a baseline period up to 5 days and a treatment period 1 day The study will provide further data on safety and tolerability of ciclesonide
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None